These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 9432648

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J, Schulze G.
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [Abstract] [Full Text] [Related]

  • 5. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 6. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
    Basso D, Fabris C, Del Favero G, Panucci A, Piccoli A, Plebani M, Pedrazzoli S, Baccaglini U, Lise M, Burlina A.
    Minerva Med; 1986 Apr 14; 77(16):613-6. PubMed ID: 3458035
    [Abstract] [Full Text] [Related]

  • 7. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug 14; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

  • 8. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A, Kessler AC.
    Eur J Clin Chem Clin Biochem; 1996 Apr 14; 34(4):377-84. PubMed ID: 8704058
    [Abstract] [Full Text] [Related]

  • 9. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS.
    Gan To Kagaku Ryoho; 1989 Apr 14; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [Abstract] [Full Text] [Related]

  • 10. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Apr 14; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 11. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P, Boadas J, González-Carro P, Mora J, Pérez C, Martínez A, Roca M, Lluís F, Farré A.
    Gastroenterol Hepatol; 1999 Apr 14; 22(7):335-41. PubMed ID: 10535205
    [Abstract] [Full Text] [Related]

  • 12. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG.
    Vopr Onkol; 2001 Apr 14; 47(3):294-7. PubMed ID: 11544826
    [Abstract] [Full Text] [Related]

  • 13. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
    Lorenz M, Happ J, Hottenrott C, Maul FD, Baum RP, Hör G, Encke A.
    Nuklearmedizin; 1986 Feb 14; 25(1):9-14. PubMed ID: 3459133
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E.
    Hepatogastroenterology; 2000 Feb 14; 47(36):1750-2. PubMed ID: 11149048
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Feb 14; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 17. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Bützow GH, Jessen K, Klapdor R, Soehendra N, Wargenau M, Classen M.
    Hepatogastroenterology; 1985 Jun 14; 32(3):141-5. PubMed ID: 2410346
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
    Tappero G, Piantino P, Cerchier A, Pecchio F.
    Minerva Med; 1985 Apr 14; 76(16):765-70. PubMed ID: 2582313
    [Abstract] [Full Text] [Related]

  • 20. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
    Hasholzner U, Stieber P, Reiter W, Zimmermann A, Hofmann K, Schalhorn A.
    Anticancer Res; 1999 Apr 14; 19(4A):2477-80. PubMed ID: 10470177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.